Puttkammer Nancy, Domerçant Jean Wysler, Adler Michelle, Yuhas Krista, Myrtil Martine, Young Paul, François Kesner, Grand'Pierre Reynold, Lowrance David
International Training and Education Center for Health (I-TECH), Department of Global Health, University of Washington, Seattle, Washington, United States of America.
US Centers for Disease Control and Prevention, Port au Prince, Haiti.
PLoS One. 2017 Mar 6;12(3):e0173123. doi: 10.1371/journal.pone.0173123. eCollection 2017.
In October 2012, the Haitian Ministry of Health endorsed the "Option B+" strategy to eliminate mother-to-child transmission of HIV and achieve HIV epidemic control. The objective of this paper is to assess and identify risk factors for attrition from the national ART program among Option B+ patients in the 12 months after ART initiation.
This retrospective cohort study included patients newly initiating ART from October 2012-August 2013 at 68 ART sites covering 45% of all newly enrolled ART patients in all regions of Haiti.
With data from electronic medical records, we carried out descriptive analysis of sociodemographic, clinical, and pregnancy-related correlates of ART attrition, and used a modified Poisson regression approach to estimate relative risks in a multivariable model.
There were 2,166 Option B+ patients who initiated ART, of whom 1,023 were not retained by 12 months (47.2%). One quarter (25.3%) dropped out within 3 months of ART initiation. Protective factors included older age, more advanced HIV disease progression, and any adherence counseling prior to ART initiation, while risk factors included starting ART late in gestation, starting ART within 7 days of HIV testing, and using an atypical ART regimen.
Our study demonstrates early ART attrition among Option B+ patients and contributes evidence on the characteristics of women who are most at risk of attrition in Haiti. Our findings highlight the importance of targeted strategies to support retention among Option B+ patients.
2012年10月,海地卫生部批准了“B+方案”,以消除母婴传播艾滋病毒并实现艾滋病毒疫情控制。本文的目的是评估并确定在开始抗逆转录病毒治疗(ART)后的12个月内,“B+方案”患者退出国家ART项目的风险因素。
这项回顾性队列研究纳入了2012年10月至2013年8月在68个ART治疗点新开始接受ART治疗的患者,这些治疗点覆盖了海地所有地区45%新登记接受ART治疗的患者。
利用电子病历数据,我们对ART治疗中断的社会人口学、临床及妊娠相关因素进行了描述性分析,并采用修正的泊松回归方法在多变量模型中估计相对风险。
共有2166名“B+方案”患者开始接受ART治疗,其中1023人在12个月内未继续接受治疗(47.2%)。四分之一(25.3%)的患者在开始ART治疗后的3个月内退出。保护因素包括年龄较大、艾滋病毒疾病进展更严重以及在开始ART治疗前接受过任何依从性咨询,而风险因素包括在妊娠后期开始ART治疗、在艾滋病毒检测后7天内开始ART治疗以及使用非典型ART治疗方案。
我们的研究表明“B+方案”患者中存在早期ART治疗中断的情况,并为海地最有可能中断治疗的女性特征提供了证据。我们的研究结果凸显了采取针对性策略以支持“B+方案”患者继续接受治疗的重要性。